STOCK TITAN
  1. Home
  2. Sec-filings
  3. KLRS
  4. [Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity

Samsara Opportunity Fund ups Kalaris Therapeutics (KLRS) stake with 479,847-share buy

Filing Impact
(Very High)
Filing Sentiment
(Very Positive)
Form Type
4

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. reported an insider-related block trade in its common stock involving affiliated investment funds. Samsara Opportunity Fund, L.P., an entity associated with director and 10% owner Srinivas Akkaraju, made an open-market style, privately negotiated purchase of 479,847 common shares at $10.42 per share from Samsara BioCapital, L.P.

Following this transaction, Samsara Opportunity Fund held 1,979,847 Kalaris Therapeutics shares, while Samsara BioCapital, L.P. held 10,968,234 shares. The filing notes that Akkaraju and related general partner entities may be deemed beneficial owners but disclaim beneficial ownership beyond their pecuniary interests, and one footnote states the transfer from Samsara BioCapital, L.P. did not change Akkaraju’s overall beneficial ownership.

Positive

  • None.

Negative

  • None.
Insider AKKARAJU SRINIVAS, Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC
Role Director, 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought 479,847 shs ($5.00M)
Type Security Shares Price Value
Purchase Common Stock 479,847 $10.42 $5.00M
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 1,979,847 shares (Indirect, By Samsara Opportunity Fund, L.P.)
Footnotes (1)
  1. Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby. Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. The shares held by Samsara LP reflects the disposition of 479,847 shares, to Samsara Opportunity Fund as described in footnote (1), in which the Reporting Person had no pecuniary interest. The transfer of such shares by Samsara LP did not involve a change in the Reporting Person's beneficial ownership of such shares and, accordingly, was exempt from reporting under Section 16. Shares held by Samsara LP. The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
AKKARAJU SRINIVAS
(Last) (First) (Middle)
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
(Street)
PALO ALTO CA 94301
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/18/2025 P(1) 479,847 A $10.42 1,979,847(2) I By Samsara Opportunity Fund, L.P.(3)
Common Stock 10,968,234(4) I By Samsara BioCapital, L.P.(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
AKKARAJU SRINIVAS
(Last) (First) (Middle)
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
(Street)
PALO ALTO CA 94301
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
X Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Samsara BioCapital, L.P.
(Last) (First) (Middle)
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
(Street)
PALO ALTO CA 94301
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Samsara BioCapital GP, LLC
(Last) (First) (Middle)
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
(Street)
PALO ALTO CA 94301
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Samsara Opportunity Fund, L.P.
(Last) (First) (Middle)
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
(Street)
PALO ALTO CA 94301
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Samsara Opportunity Fund GP, LLC
(Last) (First) (Middle)
C/O SAMSARA BIOCAPITAL, LLC
628 MIDDLEFIELD ROAD
(Street)
PALO ALTO CA 94301
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.
2. Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby.
3. Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
4. The shares held by Samsara LP reflects the disposition of 479,847 shares, to Samsara Opportunity Fund as described in footnote (1), in which the Reporting Person had no pecuniary interest. The transfer of such shares by Samsara LP did not involve a change in the Reporting Person's beneficial ownership of such shares and, accordingly, was exempt from reporting under Section 16.
5. Shares held by Samsara LP. The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara LP. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
/s/ Srinivas Akkaraju 02/17/2026
Samsara BioCapital, L.P., By: Samsara BioCapital GP, LLC, its General Partner, By /s/ Srinivas Akkaraju, Managing Member 02/17/2026
Samsara BioCapital GP, LLC, By /s/ Srinivas Akkaraju, Managing Member 02/17/2026
Samsara Opportunity Fund, L.P., By Samsara Opportunity Fund GP, LLC, its General Partner, By /s/ Srinivas Akkaraju, Managing Member 02/17/2026
Samsara Opportunity Fund GP, LLC, By /s/ Srinivas Akkaraju, Managing Member 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kalaris Therapeutics (KLRS) report in this Form 4?

The filing reports a privately negotiated purchase of 479,847 Kalaris Therapeutics common shares by Samsara Opportunity Fund, L.P. from Samsara BioCapital, L.P. The trade is coded as an open-market purchase at $10.42 per share.

Who is the key insider associated with the Kalaris Therapeutics (KLRS) Form 4?

The key insider is Srinivas Akkaraju, a director and 10% owner of Kalaris Therapeutics. He is associated with Samsara investment entities that hold Kalaris shares and may be deemed a beneficial owner, subject to pecuniary-interest-based disclaimers.

How many Kalaris Therapeutics (KLRS) shares did Samsara Opportunity Fund hold after the trade?

After the reported transaction, Samsara Opportunity Fund, L.P. held 1,979,847 Kalaris Therapeutics common shares. This reflects the addition of 479,847 shares acquired in the privately negotiated purchase from Samsara BioCapital, L.P. on the reported transaction date.

What was the price paid for Kalaris Therapeutics (KLRS) shares in the reported purchase?

The 479,847 Kalaris Therapeutics shares were purchased at $10.42 per share. The transaction is described as a privately negotiated deal and is coded as a purchase similar to an open-market or private transaction under Form 4 reporting rules.

How many Kalaris Therapeutics (KLRS) shares does Samsara BioCapital, L.P. hold after the transaction?

Samsara BioCapital, L.P. held 10,968,234 Kalaris Therapeutics common shares as of the filing date. This figure includes adjustments for prior reported purchases and reflects the disposition of 479,847 shares transferred to Samsara Opportunity Fund, L.P.

Did the Kalaris Therapeutics (KLRS) Form 4 change Srinivas Akkaraju’s beneficial ownership?

One footnote explains that the 479,847-share transfer from Samsara BioCapital, L.P. to Samsara Opportunity Fund did not change Srinivas Akkaraju’s beneficial ownership. The transfer was exempt from Section 16 reporting and he disclaims ownership beyond his pecuniary interest.